Literature DB >> 24227012

Analysis of Sartans: a review.

Izabela Muszalska1, Agnieszka Sobczak, Agnieszka Dołhań, Anna Jelińska.   

Abstract

The risk of cardiovascular diseases is closely related to hypertension, high cholesterol levels, and diabetes. When these risk factors appear together they are referred to as a metabolic syndrome. In the treatment of cardiovascular diseases, a combination of antihypertensive, hypolipemiant, and antidiabetic drugs is often applied. Diuretics (chlortalidone, hydrochlorothiazide, etc.) and angiotensin II receptors antagonist (sartans) are used to control hypertension, whereas statins (fluvastatin, simvastatin, etc.) are used to reduce cholesterol levels. This review is concerned with methods for the analysis of sartans in various matrices, such as pharmaceutical formulations, environmental and biological samples, and discusses the current status of stability studies of sartans . It also presents analytical methods for the simultaneous determination of sartans, diuretics, and statins.
© 2013 Wiley Periodicals, Inc. and the American Pharmacists Association.

Entities:  

Keywords:  analysis; chromatography; properties; sartans; solid state; spectroscopy; stability

Mesh:

Substances:

Year:  2013        PMID: 24227012     DOI: 10.1002/jps.23760

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  3 in total

1.  Dynamic Covalent Kinetic Resolution.

Authors:  Yan Zhang; Yang Zhang; Olof Ramström
Journal:  Catal Rev Sci Eng       Date:  2019-09-11       Impact factor: 20.217

2.  A multi-analyte LC-MS/MS method for screening and quantification of nitrosamines in sartans.

Authors:  Shu-Han Chang; Ching-Chia Chang; Li-Jing Wang; Wei-Ching Chen; Shu-Yu Fan; Chi-Zong Zang; Ya-Hui Hsu; Mei-Chih Lin; Su-Hsiang Tseng; Der-Yuan Wang
Journal:  J Food Drug Anal       Date:  2020-06-15       Impact factor: 6.157

3.  Pleiotropic effects of AT-1 receptor antagonists in hypoxia induced by cardiac ischaemia.

Authors:  Antonio Vitiello; Raffaele La Porta; Ugo Trama; Valentina Troiano; Francesco Ferrara
Journal:  Inflammopharmacology       Date:  2022-03-15       Impact factor: 5.093

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.